Table 1 Patient characteristics
From: A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
Number of patients (%) (N = 36) | |
|---|---|
Age | |
Median (range) | 58 (21–74) |
≥ 65 years | 10 (27.8%) |
Sex | |
Male | 33 (91.7%) |
Female | 3 (8.3%) |
Hepatocellular carcinoma etiology | |
Hepatitis B | 26 (72.2%) |
Hepatitis C | 1 (2.8%) |
Alcoholic cirrhosis | 8 (22.2%) |
Other | 1(2.8%) |
Metastastic sites | |
Lung | 22 (61.1%) |
Lymph node | 11 (30.6%) |
Bone | 9 (25.0%) |
Other | 11 (30.6%) |
ECOG PS | |
0 | 23 (63.9%) |
1 | 13 (36.1%) |
2 | 0 (0.0%) |
Any prior therapy | |
Sorafenib | 31 (86.1%) |
Locoregional therapya | 31 (86.1%) |
AFP | |
< 200 ng/mL | 22 (61.1%) |
≥ 200 ng/mL | 14 (38.9%) |
PIVKA | |
< 400 mAU/mL | 17 (47.2%) |
≥ 400 mAU/mL | 19 (52.8%) |